BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 25893413)

  • 1. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
    Markar SR; Bodnar A; Rosales J; Song G; Low DE
    Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
    Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
    Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer.
    Mayanagi S; Tsubosa Y; Omae K; Niihara M; Uchida T; Tsushima T; Yokota T; Sato H; Naito T; Yasui H
    Ann Surg Oncol; 2017 Nov; 24(12):3741-3747. PubMed ID: 28861809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?
    Watanabe M; Mine S; Nishida K; Yamada K; Shigaki H; Matsumoto A; Sano T
    Ann Surg Oncol; 2015 Dec; 22(13):4438-44. PubMed ID: 25862582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP
    Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.